Publications (139) María Díez Campelo publications

filter_list

2025

  1. AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular

    Blood Advances, Vol. 9, Núm. 1, pp. 39-53

  2. VAE-Surv: A novel approach for genetic-based clustering and prognosis prediction in myelodysplastic syndromes

    Computer Methods and Programs in Biomedicine, Vol. 261

2024

  1. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

    Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

  2. Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis

    Frontiers in Oncology, Vol. 14

  3. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 24, pp. 2873-2886

  4. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

    The Lancet Haematology, Vol. 11, Núm. 11, pp. e862-e872

  5. Germline assessment for alloHSCT candidates over 50 years: A ‘Fast-Track’ screening in myeloid neoplasms

    British Journal of Haematology, Vol. 205, Núm. 2, pp. 503-509

  6. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

  7. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 403, Núm. 10423, pp. 249-260

  8. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

    Blood, Vol. 144, Núm. 16, pp. 1722-1731

  9. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670

  10. MOSAIC: An Artificial Intelligence-Based Framework for Multimodal Analysis, Classification, and Personalized Prognostic Assessment in Rare Cancers

    JCO Clinical Cancer Informatics, Vol. 8

  11. Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response

    Frontiers in Oncology, Vol. 14

  12. Novel Gene Biomarkers Specific to Human Mesenchymal Stem Cells Isolated from Bone Marrow

    International Journal of Molecular Sciences, Vol. 25, Núm. 22

  13. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation

    JCO clinical cancer informatics, Vol. 8, pp. e2300205

  14. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide

    Nature Communications, Vol. 15, Núm. 1

  15. Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study

    Leukemia and Lymphoma

  16. Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia

    Biomarker Research

  17. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study

    Leukemia, Vol. 38, Núm. 10, pp. 2259-2265

  18. Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe

    Future Oncology, Vol. 20, Núm. 27, pp. 1993-2004